Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy

Original Research

(3071) Views  (891) Full article downloads

Authors: Giuseppe Derosa, Sibilla Anna Teresa Salvadeo

Published Date February 2008 Volume 2007:2(3) Pages 0 - 0

DOI: http://dx.doi.org/10.2147/CE.S7429

Giuseppe Derosa, Sibilla Anna Teresa Salvadeo

Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

Introduction: Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of both metformin and pioglitazone in reducing cardiovascular morbidity and mortality. The fixed-dose combination of metformin and pioglitazone appears to be a good option for treating diabetes in insulin-resistant patients.

Aims: The purpose of this article is to review the place in therapy of a fixed-dose combination of pioglitazone and metformin in the management of patients with type 2 diabetes.

Evidence review: The current evidence suggests that combined therapy may help to achieve the recommended goals in the management of diabetes. A fixed-dose formulation of pioglitazone and metformin may provide advantages in terms of glycemic control and other cardiovascular risk factors frequently associated with diabetes.

Place in therapy: The current evidence shows that a fixed-dose formulation of pioglitazone and metformin offers an effective option for the management of patients with type 2 diabetes when monotherapy fails in the achievement of the recommended standards of care.

Key words: cardiovascular risk factors, diabetes, pioglitazone, metformin, outcomes.

Other articles by Professor Giuseppe Derosa